Susquehanna International Group, LLP Galecto, Inc. Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$0.47 - $0.76 $79,125 - $127,947	168,352 New	168,352 $79,000
Q4 2023 Feb 14, 2024	BUY	$0.52 - $0.78 $14,313 - $21,469	27,525 New	27,525 $19,000
Q2 2023 Aug 11, 2023	BUY	$1.68 - $2.84 $55,270 - $93,433	32,899 Added 52.19%	95,936 $241,000
Q1 2023 May 16, 2023	BUY	$1.21 - $2.86 $30,632 - $72,403	25,316 Added 67.11%	63,037 $125,000
Q4 2022 Feb 14, 2023	SELL	$1.06 - $58.5 $15,901 - $877,558	-15,001 Reduced 28.45%	37,721 $43,000
Q3 2022 Nov 14, 2022	BUY	$1.59 - $60.0 $83,827 - $3.16 Million	52,722 New	52,722 $99,000
Q1 2022 May 16, 2022	SELL	$1.72 - $3.31 $27,458 - $52,840	-15,964 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.3 - $3.58 $36,717 - $57,151	15,964 New	15,964 $48,000

21.2K

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $143M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.